Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 21-29

  Ekins, Sean ^a,c   Bravi, Gianpaolo ^b   Ring, Barbara J ^c   Gillespie, Todd A ^c   Gillespie, Jennifer S ^c   Vandenbranden, Mark ^c   Wrighton, Steven A ^c   Wikel, James H ^d  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

^d Lilly Corporate Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXYCOUMARIN; AMFEBUTAMONE; AMITRIPTYLINE; ARTEETHER; BENZPHETAMINE; CYTOCHROME P450; DEXTROMETHORPHAN; DIAZEPAM; IMIPRAMINE; LIDOCAINE; MEPHENYTOIN; MIDAZOLAM; PHENAZONE; PICLAMILAST; RESORUFIN DERIVATIVE; TESTOSTERONE; VERAPAMIL;

ARTICLE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME CONFORMATION; MICHAELIS MENTEN KINETICS; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

ARYL HYDROCARBON HYDROXYLASES; B-LYMPHOCYTES; BINDING SITES; CATALYSIS; CELL CULTURE TECHNIQUES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; OXIDOREDUCTASES, N-DEMETHYLATING; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0032964028     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bargetzi M, Aoyama T, Gonzalez F and Meyer, U (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 46:521-527.
2. Baroni M, Coatantino G, Cruciani G, Riganelli D, Valigi R and Clementi S (1993) Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems. Quant Struct-Act Relat 12:9.
3. Boxenbaum HG, Riegelman S and Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2:123-148.
4. Bravi G, Gancia E, Mascagni P, Pegna M, Todeschini R and Zaliani A (1997) MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids. J Comput-Aided Mol Des 11:79-92.
5. Bravi G and Wikel JH (1998a) Application of MS-WHIM Descriptors: 1. Introduction of new molecular surface properties and 2. Prediction of binding affinity data. Quant Struct-Act Relat submitted
6. Bravi G and Wikel JH (1998b) Application of MS-WHIM Descriptors: 3. Prediction of molecular properties. Quant Struct-Act Rel submitted.
7. Cramer III RD, DePriest SA, Patterson DE and Hecht P (1993) The developing practice of comparative molecular field analysis, in 3D QSAR in drug design: theory, methods and applications (Kubinyi H ed) pp 443-445, ESCOM, The Netherlands.
8. de Groot MJ, Bijloo GJ, Van Acker FAA, Fonseca Guerra C, Snijders JG and Vermeulen NPE (1997) Extension of a predictive substrate model for human cytochrome P4502D6. Xenobiotica 27:357-368.
9. Ekins S, VandenBranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259.
10. Ekins S, VandenBranden M, Ring BJ and Wrighton SA (1997) Examination of purported probes of human CYP2B6. Pharmacogenetics 7:165-179.
11. Engel G, Hofmann U, Heidemann H, Cosme J and Eichelbaum M (1996) Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59:613-623.
12. m. Drug Metab Rev 28:513-526.
13. Gharamani P, Ellis SW, Lennard MS, Ramsay LE and Tucker GT (1997) Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacal 43:137-144.
14. Grace JM, Aguilar AJ, Trotman KM, Peggins JO and Brewer TG (1998) Metabolism of β-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab Dispos 26:313-317.
15. Hahn M and Rogers D (1995) Receptor Surface Models 2. Application to quantitative structure-activity relationships studies. J Med Chem 38:2091-2102.
16. Hansch C and Zhang L (1993) Quantitative structure-activity relationships of cytochrome P-450. Drug Metab Reu 25:1-48.
17. Heyn H, White RB and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948-953.
18. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y and Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Biochem Pharmacol 51:1041-1050.
19. Jones JP, He M, Trager WF and Rettie AE (1996) Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 24:1-6.
20. Kaminski JJ, Rane DF, Snow ME, Weber L, Rothofsky ML, Anderson SD and Lin SL (1997) Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods. J Med Chem 40:4103-4112.
21. Kariya S, Isozaki S, Uchino K, Suzuki T and Nahmatsu S (1996) Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull 19:1511-1514.
22. Koehler KF, Rao SN and Snyder JP (1996) Modeling drug-receptor interactions, in Guidebook on Molecular Modeling in Drug Design (Cohen NC ed) pp 235-336, Academic Press, San Diego.
23. Koyama E, Chiba K, Tani M and Ishizaki T (1997) Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: A study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 281:1199-1210.
24. Kroemer HK, Echizen H, Heidemann H and Eichelbaum M (1992) Predictability of the in vivo metabolism of verapamil from in vitro data; contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 260:1052-1057.
25. Lewis DFV and Lake BG (1997) Molecular modeling of mammalian CYP2B isoforms and their interaction with substrates, inhibitors and redox partners. Xenobiotica 27:443-478.
26. McIntyre CJ, Madan A and Parkinson A (1996) Investigation of the role of CYP2B6 in the N-demethylation of dextromethorphan by human liver microsomes. ISSX Proc 10:231.
27. Nelsestuen GL and Martinez MB (1997) Steady state enzyme velocities that are independent of [enzyme]: An important behavior in many membrane and particle-bound states. Biochemistry 38:9081-9086.
28. Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ and Satoh T (1996) Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 26: 1155-1166.
29. Poet TS, McQueen CA and Halpert JR (1996) Participation of cytochromes P4502B and P4503A in cocaine toxicity in rat hepatocytes. Drug Metab Dispos 24:74-80.
30. Segel IH (1993) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley and Sons Inc., New York.
31. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
32. Stevens JC, White RB, Hsu SH and Martinet M (1997) Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J Pharmacol Exp Ther 282:1389-1395.
33. Strobl GR, von Kruedener S, Stockigt J, Guengerich FP and Wolff T (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies. J Med Chem 36:1136-1145.
34. Wagener M, Sadowski J and Gasteiger J (1995) Autocorrelation of molecular surface properties for modeling corticosteroid binding globulin and cytosolic Ah receptor activity by neural networks. J Am Chem Soc 117:7769-7775.
35. Weininger D (1988) SMILES 1. Introduction and encoding rules. J Chem Inf Comput Sci 28:31.
36. Wold S, Johansson E and Cocchi M (1993) PLS-Partial least squares projections to latent structures, in 3:D-QSAR in Drug Design: Theory, Methods and Applications (Kubinyi H ed) pp 523-550, ESCOM, Leiden.
37. Wolf CR, Meehan RR, Miles JS, Jowett TJ, Spurr NK, Stevenson K, Forrester LM, Gosden J and Hastie N (1988) Characterization of the human homologues to rat liver phenobarbital-inducible cytochromes P-450. In Microsomes and Drug Oxidations, Proceeding of the 7th International Symposium, pp 79-88, Taylor and Francis, London.
38. Wormhoudt LW, Ploemen JHTM, de Waziers I, Commandeur JNM, Beaune PH, van Bladeren P and Vermeulen NPE (1996) Inter-individual variability in the oxidation of 1,2-dibroethane: Use of heterologously expressed human cytochrome P450 and human liver microsomes. Chem-Biol Interact 101:175-192.
39. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
40. Wurm RM, Dunn JA, Silver IS and Patel DK (1996) In vitro metabolism of bupropion by human liver microsomes and cDNA expressed human cytochrome P450's. ISSX Proc 10:371.
41. Yamazaki H, Inoue K, Mimura M, Oda Y, Guengerich FP and Shimada T (1996) 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem Pharmacol 51:313-319.